European Federation for coloRectal Cancer

Programm

14. EFR Congress
10. - 12.09.2026
Vienna



MASTERING COMPLEXITY

Precision, Preservation and Artificial Intelligence in Colorectal Cancer

Foto: Pixabay

Congress president

Béla TELEKY, Vienna
Irene KÜHRER, Vienna

Congress secretary

Gerd SILBERHUMER, Vienna

EFR Head Office

Hohe Warte 56
1190 Vienna, Austria

efr@congressorganisation.at
www.efrcancer.org

Welcome

Welcome to the **14th EFR Congress of the European Federation for Colorectal Cancer**, taking place from 10 to 12 September 2026 in Vienna.

The congress brings together leading international experts in **colorectal cancer care, research, and surgery** to discuss the latest advances in diagnosis, treatment, and interdisciplinary management.

On behalf of the Scientific Committee, it is my great pleasure to invite you to join us at the upcoming **14th International Congress** of the **EFR** (**E**uropean **F**ederation for colo**R**ectal Cancer), which will take place in **Vienna** from **September 10–12, 2026**.

This Congress will focus on the multidisciplinary treatment of Colorectal Cancer, bringing together leading experts, opinion leaders and participants from all across the globe. We are confident that your expertise and contribution will greatly enrich our scientific program.

Scientific Highlights:

- Colorectal Cancer in Younger Patients
- Microbiome and Carcinogenesis
- Immunotherapy and Precision Medicine
- Minimal Invasive and Robotic Surgery in CRC
- Multidisciplinary Approach of Pelvic Disorders
- Surgical Strategies for Rectal Cancer
- Cancer Types Associated with IBD
- Pre-Rehabilitation and Nutrition in Colorectal Cancer Care
- AI and Decision Support Systems (CDSS)

Looking forward to welcoming you to Vienna!

Best regards,

Univ.-Prof. Dr. Dr. h.c. Béla Teleky

General Information

Congress
14th EFR Congress – European Federation for ColoRectal Cancer

Focus
Multidisciplinary management of colorectal cancer including surgery, oncology, gastroenterology, radiology, pathology, and translational research.

Dates
10 – 12 September 2026

Location
Medical University of Vienna
Hörsaalzentrum
Lecture Hall 3, Level 7
Währinger Gürtel 18-20
1090 Vienna, Austria

Congress language
English

Organizers
Conference Presidents
Béla Teleky, Vienna
Irene Kührer, Vienna

Conference Secretary
Gerd Silberhumer, Vienna

EFR Head Office
Hohe Warte 56
1190 Vienna, Austria
efr@congressorganisation.at
www.efrcancer.org

Professional Congress Organizer
Linda Partl Congressorganisation
Hintere Gasse 2, 6175 Kematen i.T.
efr@congressorganisation.at
www.congressorganisation.at
www.efrcancer.org

The event EMT-26-09691 has been determined as compliant with MedTech Europe Code of Ethical Business Practice and EFPIA Code of Practice.

The Austrian Medical Association awards 24 credits for this event as part of its continuing medical education program (ID 1061138).

EFR 2026, Vienna, Austria, September 10, 2026 – September 12, 2026 LEE/2026/01073 has been accredited by the EACCME® with 15 credits
(10/09/2026: 4.5; 11/09/2026: 7.5; 12/09/2026: 3.0)

Thursday, 10.09.2026

12:00 PM - 12:30 PM	**Opening Ceremony & Presidential Address**	
	Honorary lecture: **The Role of Digitalization and Artificial Intelligence in Medicine** Markus Müller, Dean of the Medical University Vienna **Presidential addresses:** Christoph Zielinski, President of the Central European Cooperative Oncology Group (CECOG), Medical Director of Viennaer Privatklinik /Central European Cancer Center Béla Teleky, President and Founder of the EFR - European Federation for colorRectal Cancer	
12:30 PM - 2:00 PM	**Session I Oncology** Chairs: Christoph Zielinski, Irene Kührer	
12:30 PM - 12:50 PM	The optimal duration of adjuvant treatment of colon cancer	Eric van Cutsem
12:50 PM - 1:10 PM	Neoadjuvant Treatment in Colon Cancer in MSIH disease and MSS: Is the time come up to limit surgery?	Dirk Arnold
1:10 PM - 1:30 PM	Multidisciplinary Tumorboard	Irene Kührer
1:30 PM - 2:00 PM	Discussion	
2:00 PM - 2:30 PM	**Coffee Break & Industrial Exhibition**	
2:30 PM - 4:15 PM	**Session II – Resectability in advanced disease** Chairs: Robert Öllinger, Andreas Shamiyeh	
2:30 PM - 2:45 PM	Rectal cancer imaging: How to identify the different risk groups	Regina Beets-Tan
2:45 PM - 3:00 PM	Pushing the limits of respectability in CRC-liver metastasis	Patrick Starlinger
3:00 PM - 3:15 PM	Advances in pulmonary metastasectomy for CRC	Mir Hoda
3:15 PM - 3:30 PM	Interventional Radiology for CRC Metastases: Bridging Innovation and Evidence	Fredrik Waneck
3:30 PM - 3:45 PM	Transplantation for CRC Liver Metastasis and the Utility of Living Donation	Patrick Starlinger
3:45 PM - 4:00 PM	Transanal approach to rectal cancer surgery – What´s the benefit?	Walter Brunner
4:00 PM - 4:15 PM	Discussion	
4:15 PM - 4:45 PM	**Coffee Break & Industrial Exhibition**	

4:45 PM - 6:00 PM	**Special Lectures** Moderation: Béla Teleky, Irene Kührer	
4:45 PM - 5:10 PM	The Pioneer of TME: no evolution, no revolution without him	Bill Heald
5:15 PM - 5:35 PM	Defining a cCR in real-life cases – clinical, endoscopic and radiological features – outside of the ordinary	Rodrigo Perez
5:40 PM - 6:00 PM	Salvage treatment for regrowth	Martin Weiser

6:15 PM

Bus-Transfer
Welcome Reception
Q&A and Networking Event at the **Atrium, Museumsplatz 1, 1070 Vienna**
(Museumsplatz 1, 1070 Vienna - registration necessary)

Friday, 11.09.2026

8:30 AM - 10:00 AM	**Session III – AI & Technology** **Technical Excellence** Chairs: Milica Nestorovic, Oliver Strobel	
8:30 AM - 8:45 AM	MRI in Colorectal Liver Metastases: Direction, Characterization and Outcome Prediction	Ahmed Ba-Ssalamah
8:45 AM - 9:00 AM	Personalized surgery for patients with hereditary predisposition for cancer	Gabriela Möslein
9:00 AM - 9:15 AM	Precision medicine in practice: how an old drug is finding a new role in CRC	Anna Martling
9:15 AM - 9:30 AM	Transanal Surgery for Rectal Cancer: From Basic Techniques to Artificial Intelligence	Felix Aigner
9:30 AM - 9:45 AM	Pelvic exenteration - limits and outcome	Ian Jenkins
9:45 AM - 10:00 AM	Discussion	

10:00 AM - 10:30 AM — **Coffee Break & Industrial Exhibition**

10:30 AM - 12:00 PM	**Session IV – Early Cancer** Chairs: Laura Fernandez, Igor Stipančić	
10:30 AM - 10:45 AM	TNT for early rectal cancer – the ideal candidates for organ preservation	Rodrigo Perez
10:45 AM - 11:00 AM	Update on endoscopic resection techniques: From cold snare mucosectomy to endoscopic intramuscular dissection	Werner Dolak

11:00 AM - 11:15 AM	Fact check genetics for surgeons – mandatory knowledge	Gabriela Möslein
11:15 AM - 11:30 AM	Prognostic histopathological features in CRC of early onset	Evangelos Xynos
11:30 AM - 11:45 AM	The role of miRNAs in the pathogenesis of colitis-associated cancer	Adam Dziki
11:45 AM - 12:00 PM	Discussion	

12:00 PM - 1:00 PM	**Lunch and Industrial Exhibition**	

1:00 PM - 2:30 PM	**Session V – Robotic Colorectal Surgery: Measured Advancement or Technological Enthusiasm?** Chairs: Ladislav Sinkovic, Gerd Silberhumer	
1:00 PM - 1:15 PM	Augmented Reality: Moving Robotics Forward	Danilo Miskovic
1:15 PM - 1:30 PM	Robotic CME for right sided colon cancers	Matthias Turina
1:30 PM - 1:45 PM	Robotic surgery for rectal cancer: indication and oncological out comes	Amjad Parvaiz
1:45 PM - 2:00 PM	Robotic proficiency should be mandatory in colorectal centers	Michael Bergmann
2:00 PM - 2:30 PM	**Round table: Is there still a necessity for open surgery?** Moderation: Brendan Moran	

2:30 PM - 3:00 PM	**Coffee Break & Industrial Exhibition**	

2:30 PM - 3:00 PM	**Posterviewing** Chair: Irene Kührer, Enrico Cosentini	
01	A preoperative prediction model based on sTREM2 and APRI+ALBI improves the prediction of postoperative liver failure	Sören. Holst, Vienna, Austria
02	Adoption, Learning Curve, and Clinical Outcomes of Intracorporeal Anastomosis in Laparoscopic Right Colectomy: A Single-Center Cohort Study	Ali Toffaha, Doha, Quatar
03	Delayed coloanal anastomosis (turnbull–cutait procedure): a single-center experience	Marko Miladinov, Belgrade, Serbia
04	Comparison of Transanal Minimally Invasive Surgery (TAMIS) and Transanal Endoscopic Operations (TEO)	Hüseyin Sinan, Istanbul, Turkey
05	Dual PTPN2/PTPN1 inhibition augments bispecific T cell engager activity in patient-derived tumor models	Magdalena Rizk, Vienna, Austria
06	Highly Specialised Rectal Cancer Surgery Centres in the Czech Republic: Goals and Future Perspectives	Julius Orhalmi, Prague, Czechia

07	Analysis of preoperative risk factors and histopathological profile in predicting anastomosis dehiscence after surgical resection of colorectal carcinoma	Nenad Marković, Kragujevac, Serbia
08	Health-Related Quality of Life With Dual Immune Checkpoint Inhibition Plus Neoadjuvant Chemoradiotherapy in Rectal Cancer: Secondary Analysis of the Randomized CHINOREC Trial	Rebecca Zirnbauer, Vienna, Austria
09	Morbidity and Mortality of Cytoreductive Surgery with Hyperthermic Chemotherapy at a Tertiary Care Center from 2019 to 2025, Along with the Establishment of a Biobank	Clemens Quint, Vienna, Austria
10	Impact and evolution of minimal invasive surgery in a centralized colorectal service: trends, safety and oncological outcomes across 15 years	Ali Toffaha, Doha, Quatar
11	Pelvic exenteration(PE) as extreme surgical indication for locally advanced rectal cancer (LARC) in the era of promising neoadjuvant treatments	Alessio Vagliasindi, Rionero in the Vulture
12	Laparoscopic surgery for complex and non complex Crohn's disease	Janos Tajti, Szeged
13	Perioperative APRI+ALBI Score Messungen ermöglichen die Vorhersage von verzögertem postoperativen Leberversagen	J. Santol, Vienna
14	Robotic Rectopexy for Rectal Prolapse: A Single-Center Experience	Natália Hamranová, Prague
15	Obesity as a predictor of tumor response to neoadjuvant radiochemotherapy in rectal cancer	Yusif Aliyarov, Baku, Azerbaijan
16	Oncologic Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: The Impact of Cytoreduction Completeness, Tumor Burden, and Pelvic Involvement	Sezai Demirbas, Ankara
17	Outcome after Right Hemicolectomy with Special Focus on Anastomotic Leakage – A Retrospective Analysis on 641 Patients	Sandra Raab, Linz
18	Using patient-derived malignant ascitic effusions to decipher anti-tumor responses after STING agonist treatment	Carmen Dreuw, Vienna
19	Minimally Invasive Hartmann's Reversal: Short-Term Outcomes and Predictors of successful MIS in a Nine-Year Retrospective Cohort	Ali Toffaha, Doha, Quatar
20	Postoperative feeding timing and risk of gastrointestinal complications after laparoscopic colorectal cancer surgery: a retrospective cohort study	Miaoxin Huang, Budapest
21	Preoperative von Willebrand Factor Antigen Is Associated with Long-Term Survival After Resection of Colorectal Liver Metastases	Florian Lehner, Vienna

22	STING activation counteracts the immunosuppressive tumor microenvironment in complex tumor models of colorectal cancer and restores IL-15-mediated activation of natural killer cells	Daphni Ammon, Vienna
23	Meaning of a 5-year follow-up for metastasis and local recurrence in colorectal cancer	Sandra Raab, Linz
24	The distribution and pattern of metastases of colorectal cancer (CRC) in a cohort of black african patients in Sub-Saharan Cameroon	Elroy Patrick Weledji, Buea, Cameroon
25	Successful Long-Term Disease-Free Survival Following Neoadjuvant Chemoradiotherapy and Extralevator Abdominoperineal Excision (ELAPE) for Locally Advanced Rectal Cancer: A Case Report	Nenad Marković, Kragujevac, Serbia
26	From Adoption to Maturity: Learning-Curve Evolution, Clinical Outcomes, and Lessons Learned After More Than 200 Consecutive Robotic Colorectal Procedures	Ali Toffaha, Doha, Quatar
27	Colonic Stenting in Obstructing Colorectal Cancer: Is There an Opportunity for Refinement?	Ammar Aleter, Qatar
28	Beyond the Tumor: Sexual Function, Psychological Distress, and Body Image After ELAPE	Semra Dogan, Istanbul

03:00 PM - 4:50 PM	**Session VI – Organ Preservation after TNT: Evidence, Expectations and Ethical Boundaries** Chairs: Jose Azevedo, Attila Paszt	
3:00 PM - 3:10 PM	Mesh prophylaxis after laparatomy in CR surgery	Gerd Silberhumer
3:10 PM - 3:25 PM	From TNT to Watch and Wait: Evolving radiotherapy strategies for organ preservation in rectal cancer	Johannes Knoth
3:25 PM - 3:40 PM	OReCO – Optimizing Rectal Cancer Outcomes – This is our current Pelican Educational Program	Brendan Moran
3:40 PM - 3:55 PM	What to do in case of near clinical response after TNT for rectal cancer	Dieter Hahnloser
3:55 PM - 4:10 PM	TNT and a lecture on organ preservation - long term results from the OPRA study	Martin Weiser
4:10 PM - 4:25 PM	TNT in Rectal Cancer: Optimizing Treatment and Organ Preservation	Marie-Antonietta Gambacorta
4:25 PM - 4:50 PM	**Round table: Are there patients who are not eligible for TNT?** Moderation: Irene Kührer	

5:00 PM - 6:40 PM	**Session VII – Quality of Life & Long-Term Perspective** Chairs: Ingrid Haunold, Igor Stipančić	
5:00 PM - 5:15 PM	Beyond surgical cure: addressing sexual health and intimacy for women after colorectal cancer	Gabrielle von Ramshorst
5:15 PM - 5:30 PM	How does robotic approach affect patients following rectal cancer surgery? A Quality of Life Analysis	Hermann Kessler
5:30 PM - 5:45 PM	Surgical management of ulcerative colitis-associated colorectal cancer – A 20-year single-center experience	György Lázár
5:45 PM - 6:00 PM	Timing and choice of surgical therapy in Crohn's disease - long term outcomes	Lukas Unger
6:00 PM - 6:15 PM	Robotic uterine transposition: a novel fertility sparing surgery technique for young patients receiving TNT	Stephan Polterauer
6:15 PM - 6:40 PM	**Round Table: What do we know about quality of life of our patients?** Moderation: Adam Dziki	
6:45 PM		**Bus transfer**
7:15 PM - 10:00 PM	**Networking Dinner** - registration necessary **Fuhrgassl-Huber, Neustift am Walde 68, 1190 Vienna** This event will be held at a traditional Austrian venue at the invitation of the Mayor of Vienna.	

Saturday, 12.09.2026


8:30 AM - 10:00 AM	**Session VIII – Extended Surgical Boundaries** **Chairs: Julius Örhalmi, Catharina Müller**	
8:30 AM - 8:45 AM	Colorectal peritoneal metastasis management	Brendan Moran
8:45 AM - 9:00 AM	Results of low rectal resection with delayed coloanal anastomosis/ Turnbull-cutait/for low rectal cancer	Goran Barisic
9:00 AM - 9:15 AM	Treatment of anastomosis leakages, endosponge, VAC, stents	Matthias Turina
9:15 AM - 9:30 AM	Hybrid parastomal endoscopic repair (HyPER)	Marek Szczekowski
9:30 AM - 9:45 AM	TTSS good option after Low Rectal Resection Rectal	Goran Stanojevic
9:45 AM - 10:00 AM	Discussion	
10:00 AM - 10:30 AM		**Coffee Break & Industrial Exhibition**

10:30 AM - 12:15 PM	**Session IX - Beyond Radicality – Oncology** **Chairs: Velimir Markovic, Friedrich Längle**	
10:30 AM - 10:45 AM	How to become a successful researcher in this time of transition	Shahrokh Shariat
10:45 AM - 11:00 AM	Dual Immune Checkpoint Inhibition Combined with Neoadjuvant Chemoradiotherapy in Rectal Cancer: Results from the Randomized CHINOREC Trial	Johannes Längle
11:00 AM - 11:15 AM	Rectal Cancer Treatment decision upfront; are we treating too many patients with TNT?	Dirk Arnold
11:15 AM - 11:30 AM	Treatment of Anal Carcinoma in 2026	Andreas Salat
11:30 AM - 11:45 AM	Anal adenocarcinoma in inflammatory bowel disease: clincopathological features and association with fistula formation	Hermann Kessler
11:45 AM - 12:00 PM	Therapeutic strategies in patients with advanced and complicated colorectal cancer	Rossen Madjov
12:00 PM - 12:15 PM	Discussion	
12:15 PM - 12:30 PM	**Best Poster Presentations & Award Ceremony** **Chairs: Axel Hörhager, Irene Kührer**	
	1 short Presentation	
	2 short Presentation	
	3 short Presentation	

Closing

DACH
medical group
a member of AddLife Group

EINE NEUE ÄRA DER CHIRURGIE



MicroPort

WWW.DACH-MEDICAL-GROUP.COM

Medtronic
Colorectal Health

Your partner of choice in colorectal health.



Genuine support when you need it most

© 2026 Medtronic. All Rights Reserved. Printed in Europe. emea-dpg-2500069-partner-of-choice-18463173



Weitere Horizonte in 3L mCRC

10,8 MONATE MEDIANES GESAMTÜBERLEBEN[2]

Lonsurf®
Trifluridin/Tipiracil
Moving forward*

*ESMO I,A-Empfehlung MCBS4 für die Kombination von LONSURF® + Bevacizumab[3]

SUNLIGHT

LONSURF® in Kombination mit Bevazicumab[1]

Bestellen Sie rasch und unkompliziert die Originalpublikation!

FACHKURZINFORMATION LONSURF® BEZEICHNUNG DES ARZNEIMITTELS: Lonsurf 15 mg/6,14 mg Filmtabletten; Lonsurf 20 mg/8,19 mg Filmtabletten **QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG:** Lonsurf 15 mg/6,14 mg Filmtabletten: Jede Filmtablette enthält 15 mg Trifluridin und 6,14 mg Tipiracil (als Hydrochlorid). Sonstiger Bestandteil mit bekannter Wirkung: Jede Filmtablette enthält 90,735 mg Lactose-Monohydrat. Lonsurf 20 mg/8,19 mg Filmtabletten: Jede Filmtablette enthält 20 mg Trifluridin und 8,19 mg Tipiracil (als Hydrochlorid). Sonstiger Bestandteil mit bekannter Wirkung: Jede Filmtablette enthält 120,980 mg Lactose-Monohydrat. **HILFSSTOFFE:** Tablettenkern: Lactose-Monohydrat, vorverkleisterte Stärke (Mais), Stearinsäure; Filmüberzug: Lonsurf 15 mg/6,14 mg Filmtabletten: Hypromellose, Macrogol (8000), Titandioxid (E171), Magnesiumstearat; Lonsurf 20 mg/8,19 mg Filmtabletten: Hypromellose, Macrogol (8000), Titandioxid (E171), Eisen(III)-oxid (E172), Magnesiumstearat; Drucktinte: Schellack, Eisen(III)-oxid (E172), Eisen(III)-hydroxid-oxid x H2O (E172), Titandioxid (E171), Indigocarmin-Aluminiumsalz (E132), Carnaubawachs, Talkum **ANWENDUNGSGEBIETE:** Kolorektales Karzinom Lonsurf wird angewendet in Kombination mit Bevacizumab zur Behandlung von erwachsenen Patienten mit metastasiertem kolorektalem Karzinom (KRK), die zuvor bereits zwei Krebstherapien erhalten haben. Diese Therapien beinhalten Fluoropyrimidin-, Oxaliplatin- und Irinotecan-basierte Chemotherapien, Anti-VEGF- und/oder Anti-EGFR-Substanzen. Lonsurf wird angewendet als Monotherapie zur Behandlung von erwachsenen Patienten mit metastasiertem kolorektalem Karzinom (KRK), die bereits mit verfügbaren Therapien behandelt wurden oder die für diese nicht geeignet sind. Diese Therapien beinhalten Fluoropyrimidin-, Oxaliplatin- und Irinotecan-basierte Chemotherapien, Anti-VEGF- und Anti-EGFR-Substanzen. Magenkarzinom Lonsurf wird angewendet als Monotherapie zur Behandlung von erwachsenen Patienten mit metastasiertem Magenkarzinom einschließlich Adenokarzinom des gastroösophagealen Übergangs, die bereits mit mindestens zwei systemischen Therapieregimen für die fortgeschrittene Erkrankung behandelt worden sind (siehe Abschnitt 5.1 der Fachinformation). **GEGENANZEIGEN:** Überempfindlichkeit gegen die Wirkstoffe oder einen der in Abschnitt 6.1 (der Fachinformation) genannten sonstigen Bestandteile. **WIRKSTOFFGRUPPE:** Pharmakotherapeutische Gruppe: Antineoplastische Mittel, Antimetaboliten; ATC-Code: L01BC59. **NAME ODER FIRMA UND ANSCHRIFT DES PHARMAZEUTISCHEN UNTERNEHMERS:** LES LABORATOIRES SERVIER, 50 rue Carnot, 92284 Suresnes Cedex Frankreich. www.servier.com **ÖRTLICHER VERTRETER ÖSTERREICH:** Servier Austria GmbH, Tel: +43 (1) 524 39 99 **REZEPTPFLICHT/APOTHEKENPFLICHT:** Rezept- und apothekenpflichtig. **Weitere Informationen zu Warnhinweisen und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln oder sonstige Wechselwirkungen, Fertilität, Schwangerschaft und Stillzeit, Nebenwirkungen sowie Gewöhnungseffekte sind der veröffentlichten Fachinformation zu entnehmen.** Version 1.0 **REFERENZEN 1.** LONSURF® Fachinformation, Stand Juli 2023. **2.** Prager G.W. et al. (2023), N Engl J Med 388(18): 1657-1667. SUNLIGHT: Globale, prospektive, randomisierte Phase 3-Studie zu den Vorteilen von Wirksamkeit und Sicherheit von LONSURF® plus Bevacizumab im Vergleich zu LONSURF® Monotherapie bei erwachsenen Patienten mit therapierefraktärem mCRC. Patienten mussten mit 2 Standardchemotherapieregimen vorbehandelt worden sein, einen ECOG PS von 0 bis 1, sowie eine ausreichende Organfunktion ausweisen. 492 Patienten wurden 1:1 randomisiert und erhielten entweder LONSURF® p.o. 35 mg/m² 2x täglich an Tag 1-5 und 8-12, alle 28 Tage + Bevacizumab 5 mg/kg i.v. Tag 1 und 15, alle 28 Tage oder LONSURF® p.o. 35 mg/m² 2x täglich an Tag 1-5 und 8-12, alle 28 Tage bis zum Auftreten einer Krankheitsprogression oder unakzeptabler Toxizitäten. Primärer Endpunkt: Gesamtüberleben (Überlegenheit). Sekundäre Endpunkte: Progressionsfreies Überleben, objektive Ansprechrate und Krankheitskontrollrate. **3.** Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Cervantes A. et al., Ann Oncol. 2023;34(1):10-32. doi:10.1016/j.annonc.2022.10.003; ESMO Metastatic Colorectal Cancer Living Guidelines, v1.2 September 2024. **ABKÜRZUNGEN ECOG:** Eastern Cooperative Oncology Group. **EGFR:** Epidermaler Wachstumsfaktorrezeptor. **mCRC:** Metastasiertes Kolorektalkarzinom. **PS:** Performance Status. **VEGF:** Vaskulärer endothelialer Wachstumsfaktor. **3L:** Drittlinie. **LONSURF® is licensed to Servier by Taiho, co-developed globally and marketed in their respective territories.**

SERVIER


Entrepreneurship.
Entrepreneurial thinking is a mindset. As the market leader in Central and Eastern Europe, our decentralised Group structure puts local entrepreneurship at the very heart of our business strategy. We act with foresight and continuously adapt our services to the needs of the dynamic environment. Our 50 insurance companies and pension funds are daily committed to manage risk and deliver bespoke solutions to their 36 million customers across 30 countries.
Protecting what matters.
www.group.vig
VIG
VIENNA INSURANCE GROUP

Maximum Flexibility in Surgical Imaging: Synergy Vision™



Synergy exoscope



Nanoendoscopy



Near-infrared (NIR) fluorescence



NIR imaging for minimally invasive or open procedures and nanoendoscopy in one system.

endoscopy.arthrex.com

arthrex.com

© 2026-08 Arthrex GmbH. All rights reserved. AD2-000913-en-US_A

Arthrex Endoscopy

People.Health.Care.

Suprasorb®
CNP endo

Endoscopic negative pressure therapy in the upper and lower GI.

Tutorials
Dr. Gunnar Loske


Case Study
Lower GI
DDr. Peter Tschann

Case Study
Upper GI
DDr. Peter Tschann


Therapy unit
Complete system, controlled negative pressure, therapy unit with custom software



Easy connection



Foam drain
without feeding tube, lower GI and intracavitary usage



Foam drain
with feeding tube, enteral feeding and negative pressure therapy at the same time



Contact us:

www.Lohmann-Rauscher.com

Johnson&Johnson
MedTech

Introducing ETHICON™ 4000 Stapler & ETHICON™ 3D Reloads





3D Stapling Technology



Engineered for strength and stability



Expanded Tissue Ranges*

* The tissue ranges of the ETHICON™ 3D white, blue and green reloads are expanded compared to the ECHELON ENDOPATH™ GST Reloads removing the need for a Gold reload

Important Information: Please refer to the latest Instructions for Use and/or Package Insert provided by the manufacturer of the device for the details such as indications, contraindications, side effects, warnings, and precautions.

© Johnson & Johnson and its affiliates 2026. M_EM_SRG_STAP_414709

Gold

DACH medical group
a member of AddLife Group

Medtronic

Silver

Arthrex®

UNIQA

Bronze

ETHICON
PART OF THE Johnson&Johnson FAMILY OF COMPANIES

INTUITIVE

KLS martin GROUP

People.Health.Care.

Top Med

Supporters

STORZ
KARL STORZ — ENDOSKOPE

BD

XNY MEDICAL™

VIG VIENNA INSURANCE GROUP
WIENER STÄDTISCHE VIENNA INSURANCE GROUP
donau VIENNA INSURANCE GROUP
WIENER OSIGURANJE VIENNA INSURANCE GROUP
Life BULSTRAD VIENNA INSURANCE GROUP
GPI VIENNA INSURANCE GROUP
IRAO VIENNA INSURANCE GROUP

SERVIER

UNGER
www.ungersteel.com

OLYMPUS